| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.3 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.3 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.3 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.029 | 0.3 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.055 | 0.3 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.03 | 0.3 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.036 | 0.3 |